Kristie L. Kahl

Articles

Lurbinectedin Combo Induces Clinical Activity in Chemo-Sensitive SCLC

September 26th 2018

Lurbinectedin plus doxorubicin demonstrated significant clinical activity as a second-line therapy for patients with small cell lung cancer, especially when excluding refractory patients.

Entinostat/Pembrolizumab Combo Shows Promise in NSCLC Subgroup

September 26th 2018

Ongoing analyses suggest enhanced clinical benefit is derived from the combined use of entinostat and pembrolizumab in a subgroup of patients with PD-1/PD-L1–refractory non–small cell lung cancer who have high levels of peripheral blood monocytes.

Atezolizumab Prolongs Survival in SCLC

September 26th 2018

The addition of atezolizumab to standard carboplatin and etoposide in the frontline setting significantly prolonged survival in patients with extensive-stage small cell lung cancer compared with the chemotherapy regimen alone.

Brigatinib Bests Standard of Care to Improve PFS in Advanced NSCLC

September 25th 2018

Brigatinib reduced the risk of disease progression or death by more than 50% compared to crizotinib in adult patients with ALK-positive, locally advanced or metastatic NSCLC.

Adding Durvalumab to Chemoradiation Improves OS in Unresectable Stage III NSCLC

September 25th 2018

Durvalumab induced a clinically meaningful improvement in overall survival compared with placebo in patients with stage III, unresectable non–small cell lung cancer who have not progressed following chemoradiotherapy.

Atezolizumab Regimen Improves PFS in Frontline Nonsquamous NSCLC

September 25th 2018

The addition of atezolizumab to carboplatin/cisplatin in the first-line setting and to pemetrexed as maintenance therapy significantly improved progression free survival in patients with stage IV nonsquamous NSCLC.

Repotrectinib Shows Promising Activity in ROS1+ NSCLC

September 25th 2018

Repotrectinib (TPX-0005) demonstrates a clinically meaningful and durable benefit across multiple doses in patients with ROS1 fusion–positive NSCLC.

Poziotinib Shows Encouraging Activity Among Heavily Pretreated NSCLC Subgroup

September 25th 2018

Poziotinib demonstrated high antitumor activity in patients with metastatic, heavily pretreated EGFR and HER2 exon 20 mutant non–small cell lung cancer.

FDA Grants Frontline Pembrolizumab Priority Review for Lower PD-L1 Cutoff in NSCLC

September 12th 2018

The FDA has granted a priority review designation to single-agent pembrolizumab for the frontline treatment of patients with locally advanced or metastatic nonsquamous or squamous non–small cell lung cancer with PD-L1 expression ≥1% and no EGFR or ALK genomic tumor aberrations.

Heated Chemo During Resection Shows No Benefit in Advanced CRC

June 4th 2018

The addition of heated chemotherapy delivered to the abdomen during surgery delivered no survival benefit to patients with peritoneal carcinomatosis.

Frontline Pembrolizumab Bests Chemo in NSCLC, Especially in PD-L1-High Subgroup

June 3rd 2018

Patients with non-small cell lung cancer treated with frontline pembrolizuma lived 4 to 8 months longer than those who received standard of care chemotherapy.

Microsatellite Instability Status Links to Lynch Syndrome in Broad Array of Cancers

June 2nd 2018

Microsatellite instability-high tumors are more likely to be associated with the presence of Lynch syndrome. Yet, 45% of patients with cancers not typically identified with Lynch syndrome actually qualify for germline genetic testing.

Compared With Men, Women With Head and Neck Cancer Undertreated

June 1st 2018

Women with head and neck cancer may be severely undertreated and have higher death rates compared with their male counterparts.

TLR9 Agonist May Reverse Resistance to PD-1 Inhibition in Melanoma

April 17th 2018

Combination use of CMP-001, an intratumoral toll-like receptor 9 agonist, and pembrolizumab (Keytruda) showed clinical activity in reversing PD-1 checkpoint inhibition resistance in patients with metastatic melanoma.

FT819 Derives Renewable, Reproducible Process of CAR T-Cell Therapy

April 16th 2018

An off-the-shelf, dual-targeted chimeric antigen receptor T-cell approach yielded positive results in preclinical specificity, functionality, and efficacy studies.

BLU-667 Shows Promise for Advanced Solid Tumors With RET Alterations

April 15th 2018

BLU-667, a next-generation tyrosine kinase inhibitor, appeared to be well-tolerated and had broad clinical benefit among patients with advanced, RET-altered solid tumors who progressed on prior therapies.

Combination Regimen Safe, Effective as Salvage Therapy for Relapsed/Refractory Hodgkin Lymphoma

December 11th 2017

Brentuximab vedotin (Adcetris) plus nivolumab (Opdivo) appeared active and well tolerated for the treatment of patients with relapsed/refractory Hodgkin lymphoma.

Curative Approach Improves Responses in Patients With Smoldering Multiple Myeloma

December 11th 2017

A novel approach demonstrated durable responses in the treatment of patients with smoldering multiple myeloma, according to results from a single-arm, phase II trial.

Alternative Agent Shows Clinical Activity in Patients With Advanced Systemic Mastocytosis

December 10th 2017

Treatment using BLU-285 (Avapritinib) induced clinically significant activity in patients with an advanced or aggressive form of systemic mastocytosis, according to data from an ongoing phase I trial.

Direct Oral Anticoagulant Prevents VTE Recurrence in Select Patients With Cancer

December 9th 2017

Treatment using oral rivaroxaban (Xarelto) reduced venous thromboembolism (VTE) recurrence among patients with cancer, according to results from the select-d trial.